NONOF Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of -64.14%. Novo Nordisk A/S's return on equity of 62.44% beat Evaxion AS's return on equity of --.

Novo Nordisk A/S has a consensus price target of $53.99, signalling upside risk potential of 14.31%. On the other hand Evaxion AS has an analysts' consensus of $12.33 which suggests that it could grow by 294.04%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 35.045% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 3.66%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 50.28% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Evaxion AS quarterly revenues of $37.5K. Novo Nordisk A/S's net income of $4.2B is higher than Evaxion AS's net income of -$4.9M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.62x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.50x versus 2.10x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Genmab A/S has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of 39.24%. Novo Nordisk A/S's return on equity of 62.44% beat Genmab A/S's return on equity of 28.3%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling upside risk potential of 14.31%. On the other hand Genmab A/S has an analysts' consensus of $37.93 which suggests that it could grow by 18.9%. Given that Genmab A/S has higher upside potential than Novo Nordisk A/S, analysts believe Genmab A/S is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 35.045% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.054%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 3.66%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 50.28% of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Genmab A/S quarterly revenues of $1B. Novo Nordisk A/S's net income of $4.2B is higher than Genmab A/S's net income of $399.2M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.62x while Genmab A/S's PE ratio is 13.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.50x versus 5.59x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of 34.4%. Novo Nordisk A/S's return on equity of 62.44% beat Eli Lilly & Co.'s return on equity of 106.26%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling upside risk potential of 14.31%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,166.56 which suggests that it could grow by 3.87%. Given that Novo Nordisk A/S has higher upside potential than Eli Lilly & Co., analysts believe Novo Nordisk A/S is more attractive than Eli Lilly & Co..

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 35.045% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 3.66%. Eli Lilly & Co. offers a yield of 0.54% to investors and pays a quarterly dividend of $1.50 per share. Novo Nordisk A/S pays 50.28% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Novo Nordisk A/S's net income of $4.2B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.62x while Eli Lilly & Co.'s PE ratio is 48.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.50x versus 15.28x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.